| Name | IACS-13909 |
| Description | IACS-13909 (BBP-398), a specific and potent allosteric inhibitor of SHP2, that suppresses signaling through the MAPK pathway. |
| In vitro | IACS-13909 potently impeded proliferation of tumors harboring a broad spectrum of activated RTKs as the oncogenic driver. |
| In vivo | In EGFR-mutant osimertinib-resistant NSCLC models with EGFR-dependent and EGFR-independent resistance mechanisms, IACS-13909, administered as a single agent or in combination with osimertinib, potently suppressed tumor cell proliferation?in vitro?and caused tumor regression?in vivo. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 1 mg/mL (2.65 mM), Sonication is recommended. DMSO : 9 mg/mL (23.86 mM), Sonication is recommended.
|
| Keywords | SHP-2 | SHP2 | RTK | pMEK | Phosphatase | pERK | MAPK | Inhibitor | inhibit | IACS-13909 | IACS13909 | IACS 13909 | BBP398 | BBP 398 | antiproliferative | anticancer |
| Inhibitors Related | β-Glycerophosphate disodium salt pentahydrate | Hexane-1,6-diol | 2-[dodecyl(2-hydroxyethyl)amino]ethanol | Idoxuridine | Cyclosporine | Tartaric acid disodium dihydrate | Stearic acid | CaMKP Inhibitor | L-Ascorbic acid 2-phosphate magnesium | Cyclosporin A | L-Ascorbic acid 2-phosphate | β-Glycerophosphate disodium salt hydrate |
| Related Compound Libraries | Anti-Lung Cancer Compound Library | Bioactive Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | NO PAINS Compound Library | Orally Active Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Phosphatase Inhibitor Library | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |